BioXcel Therapeutics : Submission of Matters to a Vote of Security Holders Form 8 K
June 12, 2024 at 06:03 am EDT
Share
Item 1 - Election of two Class III directors for a term of office expiring on the date of the annual meeting of stockholders in 2027 and until their respective successors have been duly elected and qualified.
NOMINEE
Votes FOR
Votes
WITHHELD
Broker Non-Votes
Vimal Mehta, Ph.D.
16,490,409
2,066,701
7,552,611
Peter Mueller, Ph.D.
13,702,818
4,854,292
7,552,611
Attachments
Original Link
Permalink
Disclaimer
BioXcel Therapeutics Inc. published this content on
12 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
12 June 2024 10:02:01 UTC.
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Companyâs most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
BIOXCEL THERAPEUTICS, INC. 
